<DOC>
	<DOCNO>NCT00328458</DOCNO>
	<brief_summary>The purpose study determine safety drug EPO906 could shrink tumor use radiation therapy cancer patient .</brief_summary>
	<brief_title>EPO906 Plus Radiation Therapy Treatment Cancer Patients</brief_title>
	<detailed_description>- To determine maximum tolerate dose ( MTD ) EPO906 administer combination radiation therapy establish recommend phase II dose . - To evaluate safety toxicity profile EPO906 administer concurrently radiotherapy three disease cohort . - To evaluate tumor response .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<criteria>Requires minimum 3 week radiation therapy Solid tumor advance recurrent disease standard therapy tumor fail standard therapy World Health Organization ( WHO ) performance status equal le 2 Life expectancy equal great 3 month Any peripheral neuropathy Unresolved diarrhea great grade 1 Patients receive investigational compound within past 28 day Severe cardiac insufficiency Patients Coumadin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>CNS head neck cancer</keyword>
	<keyword>Histologically confirm CNS malignancy head neck</keyword>
	<keyword>standard therapy</keyword>
	<keyword>failed standard therapy</keyword>
</DOC>